A5081926380- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Chronic Lymphocytic Leukemia Research
- Biosimilars and Bioanalytical Methods
- Immune Cell Function and Interaction
- Acute Lymphoblastic Leukemia research
- T-cell and B-cell Immunology
- Chronic Myeloid Leukemia Treatments
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Acute Myeloid Leukemia Research
- Viral Infectious Diseases and Gene Expression in Insects
- Immunodeficiency and Autoimmune Disorders
- Biomedical Ethics and Regulation
- Multiple Myeloma Research and Treatments
- Renal Transplantation Outcomes and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Integrated Circuits and Semiconductor Failure Analysis
- Virus-based gene therapy research
- Cancer Immunotherapy and Biomarkers
- Advancements in Semiconductor Devices and Circuit Design
- Blood groups and transfusion
- Silicon Carbide Semiconductor Technologies
- Viral-associated cancers and disorders
Stanford University
2016-2025
Stanford Blood Center
2013-2024
Stanford Medicine
2014-2024
Stratford University
2019-2024
Stanford Cancer Institute
2012-2024
University Hospital and Clinics
2024
University Medical Center
2024
Palo Alto University
2022-2023
Stanford Health Care
2014-2021
Rutgers, The State University of New Jersey
2021
In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after the failure of conventional therapy.In this multicenter, 2 we enrolled 111 diffuse lymphoma, primary mediastinal or transformed follicular who had disease despite undergoing recommended prior therapy. Patients received target dose 2×106 CAR T cells per kilogram body weight receiving conditioning...
Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy a poor prognosis. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, may benefit in patients lymphoma.
PURPOSE Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell lymphoma (LBCL) on the basis of single-arm phase II ZUMA-1 trial, which showed best overall and complete response rates in infused patients 83% 58%, respectively. We report clinical outcomes with axi-cel standard-of-care (SOC) setting indication. PATIENTS AND METHODS Data were collected retrospectively from all LBCL who...
Abstract Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten 16 large B cell lymphoma (LBCL) disease after CAR19 treatment had absent or low CD19. Lower surface CD19 density pretreatment was associated To prevent relapse − lo disease, we tested a bispecific CAR targeting and/or CD22 (CD19-22.BB.z-CAR) in phase I clinical trial ( NCT03233854 ) adults relapsed/refractory acute...
Massively parallel sequencing of rearranged immune receptor genes permits detection and tracking specific cell populations in normal pathological contexts.
Abstract ZUMA-1 demonstrated a high rate of durable response and manageable safety profile with axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients refractory large B-cell lymphoma. As previously reported, prespecified clinical covariates for secondary end point analysis were not clearly predictive efficacy; these included Eastern Cooperative Oncology Group performance status (0 vs 1), age, disease subtype, stage, International...
Individual variation in the Ig germline gene repertoire leads to individual differences combinatorial diversity of Ab repertoire, but study such has been problematic. The application high-throughput DNA sequencing rearranged genes now makes this possible. thousands VDJ rearrangements from an individual, either genomic or expressed mRNA, should allow their IGHV, IGHD, and IGHJ repertoires be inferred. In addition, where previously mere glimpses could gained studies, new large data sets...
Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL). Outcomes after a 3-year follow-up in pivotal ZUMA-2 study KTE-X19 MCL are reported, including subgroups by prior (bendamustine and type Bruton tyrosine kinase inhibitor [BTKi]) or high-risk characteristics.Patients with (one to five therapies, BTKi exposure) received single infusion (2 × 106 CAR T...
In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at years in patients with refractory large B-cell lymphoma (LBCL). Here, we aimed to assess survival and safety ZUMA-1 after 5 follow-up. Eligible adults LBCL (diffuse lymphoma, primary mediastinal transformed follicular lymphoma) received lymphodepleting chemotherapy followed by axi-cel...
Abstract Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has significantly improved outcomes in the treatment of refractory or relapsed large B-cell lymphoma (LBCL). We evaluated long-term course hematologic recovery, immune reconstitution, and infectious complications 41 patients with LBCL treated axicabtagene ciloleucel (axi-cel) at a single center. Grade 3+ cytopenias occurred 97.6% within first 28 days postinfusion, most resolved by 6 months. Overall, 63.4% received red...
Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved for relapsed/refractory large B lymphoma (LBCL) and has treatment with similar efficacy across conventional LBCL subtypes. Toward patient stratification, we assessed whether tumor immune contexture influenced clinical outcomes after axi-cel. We evaluated the microenvironment (TME) of 135 pre-treatment post-treatment biopsies taken from 51 patients in ZUMA-1 phase 2 trial. uncovered...
Axicabtagene ciloleucel (axi-cel) is a standard-of-care for patients with relapsed or refractory (r/r) large B cell lymphoma who have received 2 more lines of prior therapy. Patients receiving axi-cel in the real world could broader demographic, disease, and treatment profile compared that cohort pivotal ZUMA-1 trial. The present study was conducted to evaluate outcomes therapy real-world setting. A total 1297 commercial between 2017 2020 were selected from Center International Blood Marrow...
Although the majority of patients with relapsed or refractory large B-cell lymphoma respond to axicabtagene ciloleucel (axi-cel), only a minority have durable remissions. This prospective multicenter study explored prognostic value circulating tumor DNA (ctDNA) before and after standard-of-care axi-cel for predicting patient outcomes.Lymphoma-specific variable, diversity, joining gene segments (VDJ) clonotype ctDNA sequences were frequently monitored via next-generation sequencing from time...
PURPOSE Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell lymphoma (MCL). This was on the basis of single-arm phase II ZUMA-2 trial, which showed best overall and complete response rates 91% 68%, respectively. We report clinical outcomes with brexu-cel in standard-of-care setting indication. PATIENTS AND METHODS Patients who underwent leukapheresis between August 1, 2020 December...